Skip to content

Clinical trials

Phase 3 Congenital Abnormalities trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Congenital Abnormalities Phase: Phase 3 Clear all

35 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20001
20023
20031
20042
20054
20063
20073
20086
20093
20111
20121
20241
20251

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed25
Unknown status5
Withdrawn2
Active, not recruiting1
Recruiting1
Terminated1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
European Organisation for Research and Treatment of Cancer - EORTC3
National Cancer Institute (NCI)3
Alliance for Clinical Trials in Oncology2
Kastle Therapeutics, LLC2
Vanderbilt-Ingram Cancer Center2
Azienda Ospedaliera Universitaria Integrata Verona1
Case Comprehensive Cancer Center1
Chiesi Farmaceutici S.p.A.1
Children's Oncology Group1
ECOG-ACRIN Cancer Research Group1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Congenital Abnormalities35
Leukemia, Myeloid, Acute25
Leukemia20
Leukemia, Erythroblastic, Acute14
Leukemia, Megakaryoblastic, Acute14
Leukemia, Monocytic, Acute14
Leukemia, Myelomonocytic, Acute14
Myeloproliferative Disorders13
Myelodysplastic Syndromes12
Precursor Cell Lymphoblastic Leukemia-Lymphoma12

Trials

Showing 1 to 25 of 35. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.